31 results on '"Riemekasten, G"'
Search Results
2. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
- Author
-
Blagojevic, J., Bellando-Randone, S., Abignano, G., Avouac, J., Cometi, L., Czirják, L., Denton, C. P., Distler, O., Frerix, M., Guiducci, S., Huscher, D., Jaeger, V. K., Lóránd, V., Maurer, B., Nihtyanova, S., Riemekasten, G., Siegert, E., Tarner, I. H., Vettori, S., Walker, U. A., Allanore, Y., Müller-Ladner, U., Del Galdo, F., Matucci-Cerinic, M., and EUSTAR co-workers
- Published
- 2019
- Full Text
- View/download PDF
3. Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis
- Author
-
Friedrich, S., Lüders, S., Glimm, A. M., Werner, S. G., Schmittat, G., Burmester, G. R., Backhaus, M., Riemekasten, G., and Ohrndorf, S.
- Published
- 2019
- Full Text
- View/download PDF
4. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis.
- Author
-
Bütikofer, Lukas, Varisco, Pierre A., Distler, O., Kowal-Bielecka, O., Allanore, Y., Riemekasten, G., Villiger, P. M., Adler, S., on behalf of EUSTAR collaborators, Avouac, Jérôme, Walker, Ulrich A., Guiducci, Serena, Riemekasten, Gabriele, Airò, Paolo, Hachulla, Eric, Valentini, Gabriele, Carreira, Patricia E., Cozzi, Franco, Gurman, Alexandra Balbir, and Braun-Moscovici, Yolanda
- Published
- 2020
- Full Text
- View/download PDF
5. The cytokine memory of SmD183-119-autoantigen-specific Th cells of systemic lupus erythematosus patients
- Author
-
Langer, S, Langnickel, D, Enghard, P, Burmester, GR, Hiepe, F, and Riemekasten, G
- Subjects
Poster Presentation - Published
- 2005
6. Type 1 regulatory T cells in treatment of murine lupus
- Author
-
Undeutsch, R, Humrich, J, Hahn, BH, Hiepe, F, Burmester, G, Radbruch, A, and Riemekasten, G
- Subjects
Poster Presentation - Published
- 2005
7. Characterization of kidney infiltrating T cells in the NZB/W F1 lupus model
- Author
-
Enghard, P, Langnickel, D, Burmester, GR, Hiepe, F, Radbruch, A, and Riemekasten, G
- Subjects
rheumatoid arthritis ,bias ,Databases, Factual ,data banks ,Confounding Factors, Epidemiologic ,confounding ,Arthritis, Rheumatoid ,Antirheumatic Agents ,Meeting Abstract ,randomized controlled trial ,Commentary ,cohort study ,Oral Presentation ,Drug Evaluation ,Humans ,Randomized Controlled Trials as Topic - Abstract
Observational databanks have inherent strengths and shortcomings. As in randomized controlled trials, poor design of these databanks can either exaggerate or reduce estimates of drug effectiveness and can limit generalizability. This commentary highlights selected aspects of study design, data collection and statistical analysis that can help overcome many of these inadequacies. An international metaRegister and a formal mechanism for standardizing and sharing drug data could help improve the utility of databanks. Medical journals have a vital role in enforcing a quality checklist that improves reporting.
- Published
- 2004
8. Cytokine imbalance in NZB/W mice is associated with autoantibody levels and nephritis
- Author
-
Enghard, P, Langnickel, D, Hiepe, F, Burmester, GR, and Riemekasten, G
- Subjects
Meeting Abstract - Published
- 2004
9. Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development.
- Author
-
Broen, J. C. A., Gourh, P., Vonk, M. C., Beretta, L., Niederer, F., Rueda, B., Bon, L Geurts-van., Brouwer, C., Hesselstrand, R., Herrick, A., Worthington, J., Hunzelman, N., Denton, C., Fonseca, C., Riemekasten, G., Kiener, H., Scorza, R., Simeon, C. P., Fonollosa, V., and Carreira, P.
- Subjects
GENETIC polymorphisms ,SYSTEMIC scleroderma - Abstract
The article presents an abstract of a research paper that investigates the role of the Pre B-cell colony-enhancing factor (PBEF)-1001T>G and PBEF -1543C>T polymorphisms in the genetic predisposition to systemic sclerosis (SSc) susceptibilit, submitted at the 5th European Workshop on Immune-Mediated Inflammatory Diseases in Sitges-Barcelona, Spain from December 1-3, 2010.
- Published
- 2010
- Full Text
- View/download PDF
10. Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression.
- Author
-
Broen, J. C. A., Dieude, P., Vonk, M. C., Beretta, L., Rueda, B., Herrick, A., Worthington, J., Hunzelmann, N., Riemekasten, G., Kiener, H., Scorza, R., Simeon, C. P., Fonollosa, V., Carreira, P., Ortego-Centeno, N., Gonzalez-Gay, M. A., Airò, P., Coenen, M. J. H., Aliprantis, A., and Martin, J.
- Subjects
GENETIC polymorphisms ,INTERLEUKINS - Abstract
The article presents an abstract of a research paper that analyzes polymorphisms in the interleukin 4 (IL4), interleukin 13 (IL13) and their corresponding receptors, submitted at the 5th European Workshop on Immune-Mediated Inflammatory Diseases in Sitges-Barcelona, Spain from December 1-3, 2010.
- Published
- 2010
- Full Text
- View/download PDF
11. Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry.
- Author
-
Blank N, Schmalzing M, Moinzadeh P, Oberste M, Siegert E, Müller-Ladner U, Riemekasten G, Günther C, Kötter I, Zeidler G, Pfeiffer C, Juche A, Jandova I, Ehrchen J, Susok L, Schmeiser T, Sunderkötter C, Distler JHW, Worm M, Kreuter A, Keyßer G, Lorenz HM, Krieg T, Hunzelmann N, and Henes J
- Subjects
- Humans, Male, Female, Retrospective Studies, Transplantation, Autologous, Registries, Hematopoietic Stem Cell Transplantation, Scleroderma, Systemic therapy, Scleroderma, Diffuse
- Abstract
Background: Current recommendations on the management of systemic sclerosis (SSc) suggest that autologous hematopoietic stem cell therapy (HSCT) can be a rescue therapy for patients with rapidly progressive SSc., Objectives: To assess the safety and efficacy of HSCT for patients with SSc and to compare these with non-HSCT patients in a control cohort with adjusted risk factors., Methods: A retrospective analysis of data from the multicentric German network for systemic scleroderma (DNSS) with 5000 patients with SSc. Control groups consisted of all patients with diffuse cutaneous (dc)-SSc (group A) and an adjusted high-risk cohort of male patients with Scl70-positive dc-SSc (group B)., Results: Eighty SSc patients received an HSCT 4.1 ± 4.8 years after SSc diagnosis. Among them, 86.3% had dc-SSc, 43.5% were males, and 71.3% were positive for Scl70 antibodies. The control group A (n=1513) showed a significant underrepresentation of these risk factors for mortality. When the survival of the control group B (n=240) was compared with the HSCT group, a lower mortality of the latter was observed instead. Within 5 years after HSCT, we observed an improvement of the mRSS from 17.6 ± 11.5 to 11.0 ± 8.5 (p=0.001) and a stabilization of the DLCO. We did not see differences in transplant-related mortality between patients who received HSCT within 3 years after SSc diagnosis or later., Conclusion: Our analysis of real-life data show that the distribution of risk factors for mortality is critical when HSCT cohorts are compared with non-HSCT control groups., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
12. Both T and B cells are indispensable for the development of a PBMC transfer-induced humanized mouse model for SSc.
- Author
-
Shu Y, Yue X, Wax J, Kasper B, Yin J, Wang X, Zhang L, Ahmadi M, Heidecke H, Müller A, Lamprecht P, Yu X, Riemekasten G, and Petersen F
- Subjects
- Animals, B-Lymphocytes, Disease Models, Animal, Humans, Inflammation, Mice, Leukocytes, Mononuclear, Scleroderma, Systemic
- Abstract
Background: Recently, a novel humanized mouse model for systemic sclerosis (SSc) was established by transferring peripheral blood mononuclear cells (PBMC) from patients with SSc to Rag2
-/- Il2rg-/- immunodeficient mice. Here, we aimed to investigate the role of T and B cells in this humanized mouse model., Methods: T and B cells were depleted in vitro from freshly isolated PBMC using anti-CD3 and anti-CD19 magnetic microbeads, respectively. Subsequently, PBMC and T or B cell-depleted PBMC were transferred into Rag2-/- /Il2rg-/- mice via intraperitoneal injection. Twelve weeks after the transfer, mice were sacrificed and evaluated., Results: Mice transferred with whole PBMC from SSc patients developed systemic inflammation in the lungs, kidneys, and liver, and 6 out of 11 mice died or had to be sacrificed during the experiment. By contrast, such inflammation and death were not observed in mice transferred with corresponding T or B cell-depleted PBMC. In line with this finding, transfer with whole PBMC restored the splenic white pulp composing of human T, B, and plasma cells and led to the production of a considerable amount of human autoantibodies in recipient mice, while those immunological features were rarely observed in mice that received T or B cell-depleted PBMC. In contrast to our previous findings demonstrating a transfer of the protective effect of a B cell therapy into the mouse, treatment of SSc patients with chemical immunosuppressive drugs did not affect the pathogenicity of PBMC., Conclusions: This study demonstrates that both T and B cells are indispensable for the pathogenesis of the PBMC transfer-induced mouse model for SSc., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
13. An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.
- Author
-
Hesselstrand R, Distler JHW, Riemekasten G, Wuttge DM, Törngren M, Nyhlén HC, Andersson F, Eriksson H, Sparre B, Tuvesson H, and Distler O
- Subjects
- Biomarkers, Humans, Quality of Life, Treatment Outcome, Quinolines adverse effects, Scleroderma, Systemic drug therapy
- Abstract
Objectives: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc)., Methods: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study., Results: Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for 8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase., Conclusions: Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs., Trial Registration: ClinicalTrials.gov, NCT01487551 . Registered on 7 September 2011., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
14. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.
- Author
-
Weigold F, Günther J, Pfeiffenberger M, Cabral-Marques O, Siegert E, Dragun D, Philippe A, Regensburger AK, Recke A, Yu X, Petersen F, Catar R, Biesen R, Hiepe F, Burmester GR, Heidecke H, and Riemekasten G
- Subjects
- Adult, Autoantibodies blood, Biomarkers blood, Cross-Sectional Studies, Female, Humans, Lung Diseases diagnosis, Lung Diseases epidemiology, Male, Middle Aged, Predictive Value of Tests, Respiratory Function Tests trends, Scleroderma, Systemic diagnosis, Scleroderma, Systemic epidemiology, Disease Progression, Lung physiology, Lung Diseases blood, Receptors, CXCR3 blood, Receptors, CXCR4 blood, Scleroderma, Systemic blood
- Abstract
Background: The chemokine receptors CXCR3 and CXCR4 are involved in the pathogenesis of fibrosis, a key feature of systemic sclerosis (SSc). It is hypothesized that immunoglobulin (Ig)G antibodies (abs) against these two receptors are present in patients with SSc and are associated with clinical findings., Methods: Anti-CXCR3 and anti-CXCR4 ab levels were measured in 449 sera from 327 SSc patients and in 234 sera from healthy donors (HD) by enzyme-linked immunosorbent assay (ELISA). In SSc, ab levels were compared with clinical data in a cross-sectional and longitudinal setting. Protein expression of CXCR3 and CXCR4 on peripheral blood mononuclear cells (PBMCs) was analyzed in 17 SSc patients and 8 HD by flow cytometry., Results: Anti-CXCR3 and anti-CXCR4 ab levels were different among SSc subgroups compared with HD and were highest in diffuse SSc patients. The ab levels strongly correlated with each other (r = 0.85). Patients with SSc-related interstitial lung disease (SSc-ILD) exhibited higher ab levels which negatively correlated with lung function parameters (e.g., r = -0.5 and r = -0.43 for predicted vital capacity, respectively). However, patients with deterioration of lung function showed lower anti-CXCR3/4 ab levels compared with those with stable disease. Frequencies and median fluorescence intensities (MFI) of CXCR3
+ and CXCR4+ PBMCs were lower in SSc patients compared with HD and correlated with the severity of skin and lung fibrosis. They correlated with the severity of skin and lung fibrosis., Conclusions: Anti-CXCR3/4 abs and their corresponding receptors are linked with the severity of SSc-ILD. Antibody levels discriminate patients with stable or decreasing lung function and could be used for risk stratification.- Published
- 2018
- Full Text
- View/download PDF
15. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
- Author
-
Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, and Riemekasten G
- Subjects
- Adult, Aged, Cyclophosphamide therapeutic use, Drug Therapy, Combination, Female, Humans, Lung pathology, Lung physiopathology, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial physiopathology, Male, Methotrexate therapeutic use, Middle Aged, Mycophenolic Acid therapeutic use, Precision Medicine methods, Respiratory Function Tests, Scleroderma, Systemic complications, Immunosuppressive Agents therapeutic use, Lung drug effects, Lung Diseases, Interstitial drug therapy, Scleroderma, Systemic drug therapy
- Abstract
Background: Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and after therapy are scarce., Methods: We analysed patients fulfilling American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function tests (PFT) and PFT courses during IS treatment were evaluated., Results: EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid (GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging. Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50-75% or >75%. GC showed negative trends when starting with FVC <50%. Regarding diffusing capacity for carbon monoxide (DLCO), negative DLCO trends were found in patients with MMF., Conclusions: IS is broadly prescribed in SSc-ILD. Clusters of clinical and functional characteristics guide individualised treatment. Data favour distinguished decision-making, pointing to either watchful waiting and close monitoring in the early stages or start of immunosuppressive treatment in moderately impaired lung function. Advantages of specific IS are difficult to depict due to confounding by indication. Data do not support liberal use of GC in SSc-ILD.
- Published
- 2018
- Full Text
- View/download PDF
16. Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study.
- Author
-
Friedrich S, Lüders S, Werner SG, Glimm AM, Burmester GR, Riemekasten G, Backhaus M, and Ohrndorf S
- Subjects
- Adult, Aged, Cohort Studies, Female, Hand physiopathology, Humans, Male, Middle Aged, Pilot Projects, Scleroderma, Systemic physiopathology, Young Adult, Hand blood supply, Hand diagnostic imaging, Microcirculation physiology, Optical Imaging methods, Scleroderma, Systemic diagnostic imaging
- Abstract
Background: Utilising fluorescence optical imaging (FOI), the distribution of an intravenously applied colouring agent indocyanine green (ICG) can be analysed with the potential to identify malperfusion by little to no tissue enhancement. Systemic sclerosis (SSc) is characterised by the presence of digital ulcers reflecting progressive vasculopathy. The objective was to investigate the potential of FOI in the detection of disturbed microcirculation in the hands and fingers of patients with SSc and to link FOI findings to clinical signs of ischemia such as digital ulcers and pitting scars., Methods: In this cross-sectional study, 63 patients with SSc and 26 healthy subjects were examined. FOI was performed in all 89 individuals and compared to clinical data and capillaroscopic findings assembled for the SSc cohort., Results: Healthy subjects showed initial ICG signals in their fingertips in 93.6%, SSc patients in 78.5% (limited SSc) and 43.2% (diffuse SSc). Moreover, in SSc patients, FOI findings were significantly associated with a late capillaroscopic pattern, disseminated SSc features, a diffuse SSc subtype, and the presence of digital ulcers or pitting scars. Intra- and inter-reader reliability for FOI amounted to κ = 0.786 and κ = 0.834, respectively., Conclusions: FOI is able to detect areas of reduced microcirculation in patients with SSc with high association to capillaroscopic findings. The results pave the way for future FOI investigations into its role in the prediction of complications due to an impaired acral perfusion.
- Published
- 2017
- Full Text
- View/download PDF
17. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers.
- Author
-
Kopetschke K, Klocke J, Grießbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, and Riemekasten G
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers urine, Cohort Studies, Female, Humans, Lupus Nephritis diagnosis, Male, Middle Aged, Young Adult, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, Lupus Nephritis immunology, Lupus Nephritis urine, Macrophages immunology
- Abstract
Introduction: Urinary T cells represent a reliable noninvasive biomarker for proliferative Lupus nephritis (LN). Little is known about the presence of T cell subsets, B cells and macrophages in the urine although they may further improve the validity of urinary cellular biomarkers for LN., Methods: We analyzed contemporaneous blood and urine samples of patients with active LN (n = 19), other Systemic Lupus Erythematosus (SLE) patients (n = 79) and urine samples of patients with diabetic nephropathy (DN; n = 14) and anti-neutrophil cytoplasmatic antibody (ANCA) associated vasculitis (AAV; n = 11) by flow cytometry., Results: Numbers of urinary T cells, B cells and macrophages correlated with disease activity and were significantly higher in the active LN group. Urinary T cells showed excellent distinction of patients with active LN, CD8+ T cells (AUC of ROC = 1.000) and CD4+ T cells (AUC = 0.9969) alike. CD19+ B cells (AUC = 0.7823) and CD14+ macrophages (AUC = 0.9066), as well as the clinical standard proteinuria (AUC = 0.9201), failed to reach these high standards. Patients with DN or AAV also showed increased urinary cell counts, although the CD4/CD8-ratio was significantly lower in SLE compared to in DN (p = 0.0006). Urinary CD4+ T cells of active LN patients proved to be mainly of effector memory phenotype and expressed significantly more CD40L and ki67 than corresponding blood cells. Urinary Treg counts correlated with disease activity., Conclusions: Despite of detectable urinary cell counts for B cells and macrophages, T cells remain the best urinary cellular biomarker for LN. A low CD4/CD8-ratio seems to be characteristic for LN.
- Published
- 2015
- Full Text
- View/download PDF
18. Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle.
- Author
-
Spethmann S, Rieper K, Riemekasten G, Borges AC, Schattke S, Burmester GR, Hewing B, Baumann G, Dreger H, and Knebel F
- Subjects
- Adult, Aged, Echocardiography statistics & numerical data, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Observer Variation, Pilot Projects, Prognosis, Retrospective Studies, Scleroderma, Systemic complications, Stroke Volume, Systole, Ventricular Dysfunction, Left etiology, Ventricular Function, Left, Echocardiography methods, Scleroderma, Systemic diagnostic imaging, Ventricular Dysfunction, Left diagnostic imaging
- Abstract
Background: Subclinical myocardial involvement is common in systemic sclerosis (SSc) and associated with poor prognosis. Early detection, particularly during follow-up, is important. Two-dimensional speckle tracking echocardiography (STE) has already been shown to detect early left ventricular systolic impairment in SSc patients with advanced disease. The aim of this study was to assess the ability of STE to diagnose changes in left ventricular function in patients with SSc with preserved LV ejection fraction (LVEF) and normal pulmonary pressure over time., Methods: This single-center pilot study included nineteen SSc patients without pulmonary hypertension and preserved LVEF (55.2 ± 10.8 years, 13 women, mean modified Rodnan Skin Score of 8.2 ± 6.5, median disease duration 6 ± 4.5 years). We performed STE at baseline and after two years (mean 756.6 ± 8.8 days). Pulmonary hypertension was ruled out in all patients by right heart catheterization (average mean PAP 17.7 ± 3.5 mmHg)., Results: The LVEF remained unchanged (63.3 ± 4.2% vs. 63.2 ± 5.0%, P = ns), but the global longitudinal peak systolic strain of the left ventricle was significantly lower: baseline -22.0 ± 2.3% vs. follow-up -20.8 ± 2.1% (P = 0.04). The regional analysis showed a heterogeneous distribution of segmental systolic dysfunction that did not match any particular coronary artery distribution. In contrast, the LV diastolic function remained stable during follow-up., Conclusion: STE might be a sensititive and valuable method to detect early LV systolic impairment in patients with SSc and preserved LVEF during two years. Prospective evaluations are needed for prognostic implications of these changes.
- Published
- 2014
- Full Text
- View/download PDF
19. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients.
- Author
-
Günther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radić M, Burmester GR, Dragun D, and Riemekasten G
- Subjects
- Adult, Autoantibodies immunology, Chemokines, CC immunology, Chemotaxis, Leukocyte, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Humans, Interleukin-18 immunology, Male, Middle Aged, Monocytes metabolism, Real-Time Polymerase Chain Reaction, Receptor, Angiotensin, Type 1 immunology, Receptor, Endothelin A immunology, Scleroderma, Systemic metabolism, Cell Movement, Chemokines, CC biosynthesis, Interleukin-18 biosynthesis, Monocytes immunology, Receptor, Angiotensin, Type 1 metabolism, Receptor, Endothelin A metabolism, Scleroderma, Systemic immunology
- Abstract
Introduction: Agonistic autoantibodies (Aabs) against the angiotensin II receptor type 1 (AT1R) and the endothelin receptor type A (ETAR) have been identified in patients with systemic sclerosis (SSc). In our present study, we examined the expression of the AT1R and the ETAR in human immune cells and the pathological effects mediated through these receptors by their corresponding Aabs., Methods: Protein expression of AT1R and ETAR on peripheral blood mononuclear cells (PBMCs) from healthy individuals and SSc patients was analyzed using flow cytometry, and mRNA expression of both receptors in PBMCs from healthy donors was examined by real-time PCR. In addition, PBMCs from healthy donors were stimulated in vitro with affinity-purified immunoglobulin G (IgG) fractions from SSc patients positive for AT1R and ETAR Aabs, as well as with IgG from healthy donors serving as controls. Alterations in cell surface marker expression, cytokine secretion and chemotactic motility were analyzed using flow cytometry, enzyme-linked immunosorbent assays and chemotaxis assays, respectively. The results were correlated with the characteristics and clinical findings of the IgG donors., Results: Both AT1R and ETAR were expressed on PBMCs in humans. Protein expression of both receptors was decreased in SSc patients compared with that of healthy donors and declined during the course of disease. IgG fractions of SSc patients positive for AT1R and ETAR Aabs induced T-cell migration in an Aab level-dependent manner. Moreover, IgG of SSc patients stimulated PBMCs to produce more interleukin 8 (IL-8) and chemokine (C-C motif) ligand 18 (CCL18) than did the IgG of healthy donors. All effects were significantly reduced by selective AT1R and ETAR antagonists. Statistical analysis revealed an association of SSc-IgG induced high IL-8 concentrations with an early disease stage and of high CCL18 concentrations with lung fibrosis onset and vascular complications in the respective IgG donors., Conclusion: In our present study, we could demonstrate the expression of both AT1R and ETAR on human peripheral T cells, B cells and monocytes. The decreased receptor expression in SSc patients, the inflammatory and profibrotic effects upon Aab stimulation of PBMCs in vitro and the associations with clinical findings suggest a role for Aab-induced activation of immune cells mediated by the AT1R and the ETAR in the pathogenesis or even the onset of the disease.
- Published
- 2014
- Full Text
- View/download PDF
20. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.
- Author
-
Kill A, Tabeling C, Undeutsch R, Kühl AA, Günther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, and Riemekasten G
- Subjects
- Adult, Aged, Animals, Autoantigens immunology, Cells, Cultured, Chemotaxis, Leukocyte immunology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mice, Mice, Inbred C57BL, Middle Aged, Real-Time Polymerase Chain Reaction, Angiotensins immunology, Autoantibodies immunology, Receptors, Endothelin immunology, Scleroderma, Systemic immunology, Scleroderma, Systemic physiopathology
- Abstract
Introduction: Vasculopathy, inflammatory fibrosis and functional autoantibodies (Abs) are major manifestations of systemic sclerosis (SSc). Abs directed against the angiotensin II type 1 receptor (AT₁R) and endothelin-1 type A receptor (ETAR) are associated with characteristic disease features including vascular, inflammatory, and fibrotic complications indicating their role in SSc pathogenesis. Therefore, the impact of anti-AT₁R and anti-ETAR Abs on initiation of inflammation and fibrosis was analyzed., Methods: Anti-AT₁R and anti-ETAR Ab-positive immunoglobulin G (IgG) from SSc patients (SSc-IgG) was used for experiments. Healthy donor IgG served as a normal control, and AT₁R and ETAR activation was inhibited by antagonists. Protein expression was measured with ELISA, mRNA expression with real time-PCR, endothelial repair with a scratch assay, and collagen expression with immunocytochemistry. Transendothelial neutrophil migration was measured with a culture insert system, and neutrophil ROS activation with immunofluorescence. Neutrophils in bronchoalveolar lavage fluids (BALFs) were analyzed microscopically after passive transfer of SSc-IgG or NC-IgG into naïve C57BL/6J mice. KC plasma levels were quantified by a suspension array system. Histologic analyses were performed by using light microscopy., Results: Anti-AT₁R and anti-ETAR Ab-positive SSc-IgG induced activation of human microvascular endothelial cells (HMEC-1). Elevated protein and mRNA levels of the proinflammatory chemokine interleukin-8 (IL-8, CXCL8) and elevated mRNA levels of the vascular cell adhesion molecule-1 (VCAM-1) were induced in HMEC-1. Furthermore, activation of HMEC-1 with SSc-IgG increased neutrophil migration through an endothelial cell layer and activation of reactive oxygen species (ROS). SSc-IgG decreased HMEC-1 wound repair and induced type I collagen production in healthy donor skin fibroblasts. Effects of migration, wound repair, and collagen expression were dependent on the Ab-levels. Passive transfer of anti-AT1R and anti-ETAR Ab-positive SSc-IgG into naïve C57BL/6J mice increased neutrophil BALF counts. In parallel, increased levels of the murine functional IL-8 homologue, chemokine KC, were found in the plasma of SSc-IgG-treated mice as well as structural alterations of the lungs., Conclusions: We conclude that angiotensin and endothelin-receptor activation via anti-AT₁R and anti-ETAR Abs mediate pathogenic effects, indicating their contribution to pathogenesis of SSc. Therefore, anti-AT₁R and anti-ETAR Abs could provide novel targets for therapeutic intervention in the treatment of SSc.
- Published
- 2014
- Full Text
- View/download PDF
21. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility.
- Author
-
López-Isac E, Bossini-Castillo L, Simeon CP, Egurbide MV, Alegre-Sancho JJ, Callejas JL, Roman-Ivorra JA, Freire M, Beretta L, Santaniello A, Airó P, Lunardi C, Hunzelmann N, Riemekasten G, Witte T, Kreuter A, Distler JH, Schuerwegh AJ, Vonk MC, Voskuyl AE, Shiels PG, van Laar JM, Fonseca C, Denton C, Herrick A, Worthington J, Assassi S, Koeleman BP, Mayes MD, Radstake TR, and Martin J
- Subjects
- Adult, Cohort Studies, Female, Genome-Wide Association Study, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease genetics, PPAR gamma genetics, Scleroderma, Systemic genetics
- Abstract
Introduction: A recent genome-wide association study (GWAS) comprising a French cohort of systemic sclerosis (SSc) reported several non-HLA single-nucleotide polymorphisms (SNPs) showing a nominal association in the discovery phase. We aimed to identify previously overlooked susceptibility variants by using a follow-up strategy., Methods: Sixty-six non-HLA SNPs showing a P value <10⁻⁴ in the discovery phase of the French SSc GWAS were analyzed in the first step of this study, performing a meta-analysis that combined data from the two published SSc GWASs. A total of 2,921 SSc patients and 6,963 healthy controls were included in this first phase. Two SNPs, PPARG rs310746 and CHRNA9 rs6832151, were selected for genotyping in the replication cohort (1,068 SSc patients and 6,762 healthy controls) based on the results of the first step. Genotyping was performed by using TaqMan SNP genotyping assays., Results: We observed nominal associations for both PPARG rs310746 (PMH = 1.90 × 10⁻⁶, OR, 1.28) and CHRNA9 rs6832151 (PMH = 4.30 × 10⁻⁶, OR, 1.17) genetic variants with SSc in the first step of our study. In the replication phase, we observed a trend of association for PPARG rs310746 (P value = 0.066; OR, 1.17). The combined overall Mantel-Haenszel meta-analysis of all the cohorts included in the present study revealed that PPARG rs310746 remained associated with SSc with a nominal non-genome-wide significant P value (PMH = 5.00 × 10⁻⁷; OR, 1.25). No evidence of association was observed for CHRNA9 rs6832151 either in the replication phase or in the overall pooled analysis., Conclusion: Our results suggest a role of PPARG gene in the development of SSc.
- Published
- 2014
- Full Text
- View/download PDF
22. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.
- Author
-
Weigert O, von Spee C, Undeutsch R, Kloke L, Humrich JY, and Riemekasten G
- Subjects
- Animals, Combined Modality Therapy, Cyclophosphamide administration & dosage, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Immunosuppressive Agents administration & dosage, Mice, Remission Induction, T-Lymphocyte Subsets immunology, T-Lymphocytes, Regulatory immunology, Adoptive Transfer methods, Lupus Erythematosus, Systemic immunology, T-Lymphocyte Subsets transplantation, T-Lymphocytes, Regulatory transplantation
- Abstract
Introduction: The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon)., Methods: Remission of disease was induced in diseased (NZBxNZW) F1 mice with an established CTX regimen consisting of a single dose of glucocorticosteroids followed by five day course with daily injections of CTX. Five days after the last CTX injection, differing amounts of purified CD4+Foxp3+CD25+ Treg were adoptively transferred and clinical parameters, autoantibody titers, the survival and changes in peripheral blood lymphocyte subsets were determined at different time points during the study. The influence of CTX on the numbers, frequencies and proliferation of endogenous Treg and Tcon was analyzed in lymphoid organs by flow cytometry., Results: Apart from abrogating the proliferation of Tcon, we found that treatment with CTX induced also a significant inhibition of Treg proliferation and a decline in Treg numbers in lymphoid organs. Additional adoptive transfer of 1.5×10⁶ purified Treg after the CTX regimen significantly increased the survival and prolonged the interval of remission by approximately five weeks compared to mice that received only the CTX regimen. The additional clinical amelioration was associated with an increase in the Treg frequency in the peripheral blood indicating a compensation of CTX-induced Treg deficiency by the Treg transfer., Conclusions: Treg were capable to prolong the interval of remission induced by conventional cytostatic drugs. This study provides valuable information and a first proof-of-concept for the feasibility of a Treg-based immunotherapy in the maintenance of disease remission in SLE.
- Published
- 2013
- Full Text
- View/download PDF
23. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis.
- Author
-
Teruel M, Simeon CP, Broen J, Vonk MC, Carreira P, Camps MT, García-Portales R, Delgado-Frías E, Gallego M, Espinosa G, Beretta L, Airó P, Lunardi C, Riemekasten G, Witte T, Krieg T, Kreuter A, Distler JH, Hunzelmann N, Koeleman BP, Voskuyl AE, Schuerwegh AJ, González-Gay MA, Radstake TR, and Martin J
- Subjects
- Genotype, Humans, CD40 Antigens genetics, CD40 Ligand genetics, Genetic Predisposition to Disease genetics, Polymorphism, Single Nucleotide, Scleroderma, Systemic genetics
- Abstract
Introduction: The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc)., Methods: In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain, Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an association exists between the genetic variants and SSc or its main clinical subtypes., Results: No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the clinical subtypes, the serologic features, and pulmonary fibrosis., Conclusions: Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the susceptibility to or clinical expression of SSc.
- Published
- 2012
- Full Text
- View/download PDF
24. Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.
- Author
-
Foocharoen C, Tyndall A, Hachulla E, Rosato E, Allanore Y, Farge-Bancel D, Caramaschi P, Airó P, Nikolaevna SM, Pereira da Silva JA, Stamenkovic B, Riemekasten G, Rednic S, Sibilia J, Wiland P, Tarner I, Smith V, Onken AT, Abdel Atty Mohamed WA, Distler O, Morović-Vergles J, Himsel A, de la Peña Lefebvre PG, Hügle T, and Walker UA
- Subjects
- Adult, Databases, Factual statistics & numerical data, Erectile Dysfunction complications, Erectile Dysfunction drug therapy, Humans, Kidney Diseases complications, Male, Middle Aged, Muscular Diseases complications, Piperazines therapeutic use, Prospective Studies, Purines therapeutic use, Scleroderma, Systemic complications, Severity of Illness Index, Sildenafil Citrate, Skin Diseases complications, Sulfones therapeutic use, Surveys and Questionnaires, Treatment Outcome, Vasodilator Agents therapeutic use, Erectile Dysfunction physiopathology, Kidney Diseases physiopathology, Muscular Diseases physiopathology, Scleroderma, Systemic physiopathology, Skin Diseases physiopathology
- Abstract
Introduction: Erectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk factors and treatment coverage for ED are not well known., Method: This study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research database by amending the electronic data-entry system with the International Index of Erectile Function-5 and items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research substudy were asked to recruit patients consecutively., Results: Of the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the manifestation of the first non-Raynaud's symptom (median delay 4.1 years). ED was associated with severe cutaneous, muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only 27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients., Conclusions: Severe ED is a common and early problem in men with SSc. Physicians should address modifiable risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial impact of ED is needed.
- Published
- 2012
- Full Text
- View/download PDF
25. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.
- Author
-
Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, Buslau M, Worm M, Blank N, Hein R, Müller-Ladner U, Kuhn A, Sunderkötter C, Juche A, Pfeiffer C, Fiehn C, Sticherling M, Lehmann P, Stadler R, Schulze-Lohoff E, Seitz C, Foeldvari I, Krieg T, Genth E, and Hunzelmann N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Germany epidemiology, Humans, Male, Middle Aged, Multicenter Studies as Topic, Organ Specificity immunology, Scleroderma, Systemic blood, Young Adult, Antibodies, Antinuclear biosynthesis, Antibodies, Antinuclear blood, Autoantibodies biosynthesis, Autoantibodies blood, Registries, Scleroderma, Systemic diagnosis, Scleroderma, Systemic epidemiology
- Abstract
Introduction: In the present study, we analysed in detail nuclear autoantibodies and their associations in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry., Methods: Sera of 863 patients were analysed according to a standardised protocol including immunofluorescence, immunoprecipitation, line immunoassay and immunodiffusion., Results: Antinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least one of the autoantibodies highly associated with SSc or with overlap syndromes with scleroderma features was detected, that is, anti-centromere (35.9%) or anti-topoisomerase I (30.1%), followed in markedly lower frequency by antibodies to PM-Scl (4.9%), U1-ribonucleoprotein (U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%), aminoacyl-transfer RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional autoantibodies were detected in 55.4% of the patients with SSc, of which anti-Ro/anti-La, anti-mitochondrial and anti-p25/p23 antibodies were most frequent. The coexistence of SSc-associated and other autoantibodies was common (43% of patients). SSc-associated autoantibodies disclosed characteristic associations with clinical features of patients, some of which were previously not acknowledged., Conclusions: This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl, U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and characterise around 79% of all SSc patients in a central European cohort. These data confirm and extend previous data underlining the central role of the determination of ANAs in defining the diagnosis, subset allocation and prognosis of SSc patients.
- Published
- 2011
- Full Text
- View/download PDF
26. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study.
- Author
-
Schattke S, Knebel F, Grohmann A, Dreger H, Kmezik F, Riemekasten G, Baumann G, and Borges AC
- Subjects
- Adult, Aged, Early Diagnosis, Echocardiography, Doppler statistics & numerical data, Female, Humans, Hypertension, Pulmonary, Male, Middle Aged, Observer Variation, Predictive Value of Tests, Pulsatile Flow, Respiratory Function Tests, Stroke Volume, Systole, Ventricular Dysfunction, Right complications, Ventricular Function, Right, Echocardiography, Doppler methods, Echocardiography, Doppler standards, Scleroderma, Systemic complications, Ventricular Dysfunction, Right diagnostic imaging
- Abstract
Background: Isovolumetric acceleration (IVA) is a novel tissue Doppler parameter for the assessment of systolic function. The aim of this study was to evaluate IVA as an early parameter for the detection of right ventricular (RV) systolic dysfunction in patients with systemic sclerosis (SSc) without pulmonary hypertension., Methods: 22 patients and 22 gender- and age-matched healthy subjects underwent standard echocardiography with tissue Doppler imaging (TDI) and speckle tracking strain to assess RV function., Results: Tricuspid annular plane systolic excursion (TAPSE) (23.2 +/- 4.1 mm vs. 26.5 +/- 2.9 mm, p < 0.006), peak myocardial systolic velocity (Sm) (11.6 +/- 2.3 cm/s vs. 13.9 +/- 2.7 cm/s, p = 0.005), isovolumetric contraction velocity (IVV) (10.3 +/- 3 cm/s vs. 14.8 +/- 3 cm/s, p < 0.001) and IVA (2.3 +/- 0.4 m/s2 vs. 4.1 +/- 0.8 m/s2, p < 0.001) were significant lower in the patient group. IVA was the best parameter to predict early systolic dysfunction with an area under the curve of 0.988., Conclusion: IVA is a useful tool with high-predictive power to detect early right ventricular systolic impairment in patients with SSc and without pulmonary hypertension.
- Published
- 2010
- Full Text
- View/download PDF
27. Clinical and serological evaluation of a novel CENP-A peptide based ELISA.
- Author
-
Mahler M, Maes L, Blockmans D, Westhovens R, Bossuyt X, Riemekasten G, Schneider S, Hiepe F, Swart A, Gürtler I, Egerer K, Fooke M, and Fritzler MJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers blood, Case-Control Studies, Centromere Protein A, Centromere Protein B immunology, Female, Humans, Male, Middle Aged, ROC Curve, Scleroderma, Systemic immunology, Sensitivity and Specificity, Young Adult, Autoantibodies blood, Autoantigens immunology, Chromosomal Proteins, Non-Histone immunology, Enzyme-Linked Immunosorbent Assay methods, Scleroderma, Systemic blood
- Abstract
Introduction: Anti-centromere antibodies (ACA) are useful biomarkers in the diagnosis of systemic sclerosis (SSc). ACA are found in 20 to 40% of SSc patients and, albeit with lower prevalence, in patients with other systemic autoimmune rheumatic diseases. Historically, ACA were detected by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed by immunoassays using recombinant CENP-B. The objective of this study was to evaluate a novel CENP-A peptide ELISA., Methods: Sera collected from SSc patients (n=334) and various other diseases (n=619) and from healthy controls (n=175) were tested for anti-CENP-A antibodies by the novel CENP-A enzyme linked immunosorbent assay (ELISA). Furthermore, ACA were determined in the disease cohorts by IIF (ImmunoConcepts, Sacramento, CA, USA), CENP-B ELISA (Dr. Fooke), EliA CENP (Phadia, Freiburg, Germany) and line-immunoassay (LIA, Mikrogen, Neuried, Germany). Serological and clinical associations of anti-CENP-A with other autoantibodies were conducted in one participating centre. Inhibition experiments with either the CENP-A peptide or recombinant CENP-B were carried out to analyse the specificity of anti-CENP-A and -B antibodies., Results: The CENP-A ELISA results were in good agreement with other ACA detection methods. According to the kappa method, the qualitative agreements were: 0.73 (vs. IIF), 0.81 (vs. LIA), 0.86 (vs. CENP-B ELISA) and 0.97 (vs. EliA CENP). The quantitative comparison between CENP-A and CENP-B ELISA using 265 samples revealed a correlation value of rho=0.5 (by Spearman equation). The receiver operating characteristic analysis indicated that the discrimination between SSc patients (n=131) and various controls (n=134) was significantly better using the CENP-A as compared to CENP-B ELISA (P<0.0001). Modified Rodnan skin score was significantly lower in the CENP-A negative group compared to the positive patients (P=0.013). Inhibition experiments revealed no significant cross reactivity of anti-CENP-A and anti-CENP-B antibodies. Statistically relevant differences for gender ratio (P=0.0103), specific joint involvement (Jaccoud) (P=0.0006) and anti-phospholipid syndrome (P=0.0157) between ACA positive SLE patients and the entire SLE cohort were observed., Conclusions: Anti-CENP-A antibodies as determined by peptide ELISA represent a sensitive, specific and independent marker for the detection of ACA and are useful biomarkers for the diagnosis of SSc. Our data suggest that anti-CENP-A antibodies are a more specific biomarker for SSc than antibodies to CENP-B. Furthers studies are required to verify these findings.
- Published
- 2010
- Full Text
- View/download PDF
28. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.
- Author
-
Hanke K, Dähnrich C, Brückner CS, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Hiepe F, Burmester GR, Schlumberger W, and Riemekasten G
- Subjects
- Autoantigens immunology, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoblotting, Male, Middle Aged, Prognosis, Scleroderma, Systemic pathology, Sensitivity and Specificity, Autoantibodies blood, Biomarkers blood, DNA Topoisomerases, Type I immunology, Scleroderma, Systemic blood, Scleroderma, Systemic diagnosis
- Abstract
Introduction: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort., Methods: Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network., Results: The applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, rho = 0.234, rho = 0.413, rho = -0.215, rho = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003)., Conclusions: Diagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis.
- Published
- 2009
- Full Text
- View/download PDF
29. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.
- Author
-
Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Olski TM, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, and Weber M
- Subjects
- Female, Humans, Male, Registries, Adrenal Cortex Hormones therapeutic use, Immunosuppressive Agents therapeutic use, Scleroderma, Systemic drug therapy
- Abstract
Introduction: In systemic sclerosis (SSc) little evidence for the effectiveness of anti-inflammatory and immunosuppressive therapy exists. The objective of this study was to determine the extent to which SSc patients are treated with corticosteroids and immunosuppressive agents., Methods: Data on duration and dosage of corticosteroids and on the type of immunosuppressive agent were analyzed from 1,729 patients who were registered in the German Network for Systemic Scleroderma (DNSS)., Results: A total 41.3% of all registered SSc patients was treated with corticosteroids. Corticosteroid use was reported in 49.1% of patients with diffuse cutaneous SSc and 31.3% of patients with limited cutaneous SSc (P < 0.0001). Among patients with overlap disease characteristics, 63.5% received corticosteroids (P < 0.0001 vs. limited cutaneous SSc). A total 16.1% of the patients received corticosteroids with a daily dose >or= 15 mg prednisone equivalent. Immunosuppressive therapy was prescribed in 35.8% of patients. Again, among those patients with overlap symptoms, a much higher proportion (64.1%) was treated with immunosuppressive agents, compared with 46.4% of those with diffuse cutaneous SSc sclerosis and 22.2% of those with limited cutaneous SSc (P < 0.0001). The most commonly prescribed drugs were methotrexate (30.5%), cyclophosphamide (22.2%), azathioprine (21.8%) and (hydroxy)chloroquine (7.2%). The use of these compounds varied significantly between medical subspecialties., Conclusions: Despite limited evidence for the effectiveness of corticosteroids and immunosuppressive agents in SSc, these potentially harmful drugs are frequently prescribed to patients with all forms of SSc. Therefore, this study indicates the need to develop and communicate adequate treatment recommendations.
- Published
- 2009
- Full Text
- View/download PDF
30. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
- Author
-
Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, Becker MO, Huscher D, Burmester GR, and Riemekasten G
- Subjects
- Adult, Aged, Bronchoalveolar Lavage Fluid chemistry, Chemokines analysis, Cross-Sectional Studies, Cytokines analysis, Cytokines immunology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Lung Diseases, Interstitial immunology, Male, Middle Aged, Prognosis, Scleroderma, Systemic immunology, Biomarkers analysis, Bronchoalveolar Lavage Fluid immunology, Chemokines immunology, Lung Diseases, Interstitial etiology, Scleroderma, Systemic complications
- Abstract
Introduction: Interstitial lung disease (ILD) is a frequent manifestation of systemic sclerosis (SSc), and cytokines can contribute to the disease pathology. The aim of the current study was to identify specific changes in cytokine levels that may serve as disease markers and possible targets for therapy., Methods: Cytokines were measured with bioplex analysis in 38 bronchoalveolar fluids (BALFs) from 32 SSc patients (27 with alveolitis and 11 without alveolitis) and 26 control patients. In the case of SSc patients, cytokines were correlated with the respective bronchoalveolar lavage (BAL) cell differentiation, lung function, and thoracic HR-CT score. For 35 BALF samples derived from 29 SSc patients, follow-up investigations of clinical data, lung-function parameter, or thoracic HR-CT scans were available to evaluate the predictive capacity of BALF cytokines and chemokines., Results: High IL-7 levels were characteristic of SSc-associated interstitial lung disease (ILD) and, in addition, when compared with ILD-negative SSc patients, ILD-positive SSc patients revealed higher IL-4, IL-6, IL-8, and CCL2 (MCP-1) BALF levels. High CCL2 and IL-8 BALF concentrations were associated with neutrophilic and mixed alveolitis. Cytokine levels of IL-4, IL-8, and CCL2 correlated negatively with lung-function parameters; CCL2 concentrations also correlated with HR-CT scores. High concentrations of several cytokines were associated with the progress of ILD and end-stage ILD. Univariate analyses revealed high IL-2 and tumor necrosis factor-alpha (TNF-alpha) levels as the best predictors for progressive disease, together with lung-function parameters, young age, and neutrophilic alveolitis. Multivariate analyses partially confirmed these results but did not sufficiently converge because of the limited number of patients., Conclusions: The association of BALF cytokines with lung fibrosis and its progress suggests that cytokines contribute to the pathogenesis of ILD and hence could be regarded as potential therapeutic targets.
- Published
- 2009
- Full Text
- View/download PDF
31. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
- Author
-
Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W, Janssen A, Backhaus M, Becker M, Kill A, Egerer K, Burmester GR, Hiepe F, Schlumberger W, and Riemekasten G
- Subjects
- Exoribonucleases, Exosome Multienzyme Ribonuclease Complex, Humans, Immunoblotting, Middle Aged, Scleroderma, Systemic physiopathology, Sensitivity and Specificity, Autoantibodies blood, Autoantibodies immunology, Autoantigens immunology, Biomarkers blood, Scleroderma, Systemic blood, Scleroderma, Systemic immunology
- Abstract
Introduction: Anti-PM/Scl antibodies are present in sera from patients with polymyositis (PM), systemic sclerosis (SSc), and PM/SSc overlap syndromes. The prevalence of antibodies against the 75- and 100-kDa PM/Scl proteins and their clinical associations have not been studied in SSc patients in detail so far but could provide a valuable tool for risk assessment in these patients. Furthermore, it remains speculative whether commercially available test systems detecting only anti-PM/Scl-100 antibodies are sufficient in SSc patients., Methods: Two hundred eighty sera from SSc patients, patients with other connective tissue diseases (n = 209), and healthy blood donors (n = 50) were analyzed for the presence of anti-PM/Scl-75 and anti-PM/Scl-100 antibodies by means of line immunoblot assay. For the SSc patients, possible associations between both subsets of anti-PM/Scl antibodies with clinical and laboratory findings were studied., Results: The determination of anti-PM/Scl reactivity revealed a diagnostic sensitivity of 12.5% and a specificity of 96.9% for SSc. Among anti-PM/Scl-positive SSc patients, 10.4% and 7.1% were positive for anti-PM/Scl-75 and anti-PM/Scl-100 antibodies, respectively. The highest prevalences of reactivity to PM/Scl were detected in diffuse SSc (19.8%) and overlap syndromes (17.6%). Patients with diffuse SSc showed mainly an anti-PM/Scl-75 response, whereas most cases of overlap syndromes were characterized by reactivity to both PM/Scl antigens. The presence of anti-PM/Scl-75/100 antibodies was associated with muscular and lung involvements as well as with digital ulcers; pulmonary arterial hypertension was found less frequently. Anti-PM/Scl-75 antibodies were detected more frequently in younger and more active patients with joint contractures. Anti-PM/Scl-100 antibodies were associated with creatine kinase elevation; however, gastrointestinal involvements were observed less frequently., Conclusions: Anti-PM/Scl antibodies are common in distinct SSc subsets and are associated with several clinical symptoms. They are directed mainly to the PM/Scl-75 antigen. Consequently, the detection of anti-PM/Scl antibodies by tests based only on PM/Scl-100 as an antigen source may miss a relevant number of SSc patients positive for these antibodies.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.